Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster

Summary

This study is to evaluate the safety and immunogenicity of a SARS-CoV-2 mRNA Vaccine as a heterologous booster dose in adults who completed 2 doses of inactivated vaccination through 12 months in China.

Timeline

Start

2022-05-16

Primary completion

2022-06-13

Completion

2023-05-12

Publications

• Yong X, He J, Zhang C, Wang Y, Ou Y, Zhang B. Heterologous RBMRNA-405 mRNA booster enhances humoral immunity post-inactivated COVID-19 vaccination: a randomized clinical trial in adults and older through 12 months. Sci Rep. 2026 Mar 25;16(1):14928. doi: 10.1038/s41598-026-45429-w.

Drugs

Indications